The influence of cinanserin and selected pharmacologic agents on experimental allergic encephalomyelitis (EAE).
D006916:5-Hydroxytryptophan / Q000627:therapeutic use; D000661:Amphetamine / Q000627:therapeutic use; D000813:Anilides / Q000627:therapeutic use*; D000818:Animals; D001379:Azathioprine / Q000627:therapeutic use; D001835:Body Weight; D002744:Chlorpheniramine / Q000627:therapeutic use; D002934:Cinnamates / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004195:Disease Models, Animal; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D005260:Female; D010134:Fenclonine / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015122:Mercaptopurine / Q000627:therapeutic use; D008744:Methylamines / Q000627:therapeutic use; D008784:Methysergide / Q000627:therapeutic use; D010243:Paralysis / Q000188:drug therapy; D051381:Rats; D012110:Reserpine / Q000627:therapeutic use; D012702:Serotonin Antagonists; D013747:Tetrabenazine / Q000627:therapeutic use; D013997:Time Factors; D014191:Tranylcypromine / Q000627:therapeutic use
D000813:Anilides; D002934:Cinnamates; D007166:Immunosuppressive Agents; D008744:Methylamines; D012702:Serotonin Antagonists; D014191:Tranylcypromine; D002744:Chlorpheniramine; D012110:Reserpine; D003520:Cyclophosphamide; D006916:5-Hydroxytryptophan; D000661:Amphetamine; D015122:Mercaptopurine; D001379:Azathioprine; D010134:Fenclonine; D008784:Methysergide; D013747:Tetrabenazine